Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The sickle-induced non-selective cation leak pathway, commonly known as Psickle, is a deoxygenation-induced membrane conductance characteristic of red blood cells (RBCs) in sickle cell disease (SCD) [1, 3]. Upon deoxygenation and the subsequent polymerization of hemoglobin S (HbS), the RBC membrane becomes permeable to cations, allowing the influx of calcium (Ca2+) and sodium (Na+) and the efflux of potassium (K+) [1, 6]. This ion flux leads to cellular dehydration, which increases the intracellular concentration of HbS and further promotes polymerization and sickling, creating a pathophysiological cycle of cell damage [3, 8]. While its exact molecular identity has been a subject of research, recent evidence identifies the mechanosensitive ion channel PIEZO1 as a primary component, with additional contributions from N-methyl-D-aspartate (NMDA) receptors and potentially other channels like TRPC6 or Aquaporin-1 [3, 4, 10]. Pharmacological targeting of this pathway, such as through NMDA receptor antagonists like memantine or PIEZO1 inhibitors, aims to prevent the calcium-induced activation of the Gárdos channel and the resulting dehydration, offering a therapeutic strategy to improve RBC survival and reduce vaso-occlusive complications in SCD patients [4, 5, 6].
Inhibition of the non-selective cation conductance to prevent calcium influx and subsequent activation of the Gárdos channel, thereby reducing red blood cell dehydration and sickling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Deoxygenation-induced cation conductance (Psickle).